In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7 % isolated from HAP, 46.8 % from SSTI and 29.5 % from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus, 867 methicillin-sensitive Staphylococcusaureus, 299 coagulase-negative Staphylococcus (CoNS), 104 Enterococcus faecalis, 99 Enterococcusfaecium, 13 Streptococcus pneumoniae, 23 α-haemolytic Streptococcus and 103 β-haemolytic Streptococcus. MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high in vitro activity against Gram-positive pathogens (≥98.0 % susceptible), and tedizolid exhibited four- to eight fold greater activity than linezolid against the pathogens tested, with MIC90s of methicillin-resistant Staphylococcus aureus, α-haemolytic Streptococcus and β-haemolytic Streptococcus (0.25 vs 2 µg ml−1); methicillin-sensitive Staphylococcu saureus, E. faecalis and E. faecium (0.5 vs 2 µg ml−1); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 µg ml−1); and Streptococcuspneumoniae (0.125 vs 0.5 µg ml−1). Tedizolid MIC90s associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.
DourosA.,
GrabowskiK.,
StahlmannR.2015; Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 11:1849–1859 [View Article][PubMed]
GuoY.,
WangH.,
ZhaoC.,
WangZ.,
ZhangF.,
CaoB.,
HuB.,
LiaoK.,
MeiY. et al.2012; Antimicrobial resistance surveillance of gram-positive cocci isolated from 14 hospitals in China in 2011. Chin J Lab Med 35:1021–2028 (in Chinese)
GuoY.,
WangH.,
ZhaoC.,
WangZ.,
CaoB.,
XuY.,
HuB.,
NiY.,
ZhangL. et al.2013; A surveillance study of antimicrobial resistance of gram-positive cocci strains isolated from 16 teaching hospitals in China in 2012. Chin J Microbiol Immunol 33:401–409 (in Chinese)
GuoY.,
WangH.,
ZhaoC.,
ZhangF.,
WangZ.,
CaoB.,
XuY.,
ChenM.,
HuB. et al.2015; Antimicrobial resistance surveillance of gram-positive cocci isolated from 15 teaching hospitals in China in 2013. Chin J Lab Med 38:1–10 (in Chinese)
KisgenJ. J.,
MansourH.,
UngerN. R.,
ChildsL. M.2014; Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 71:621–633 [View Article][PubMed]
LeclercqR.,
DerlotE.,
DuvalJ.,
CourvalinP.1988; Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium
. N Engl J Med 319:157–161 [View Article][PubMed]
MoranG. J.,
FangE.,
CoreyG. R.,
DasA. F.,
De AndaC.,
ProkocimerP.2014; Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705 [View Article][PubMed]
ProkocimerP.,
De AndaC.,
FangE.,
MehraP.,
DasA.2013; Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559–569 [View Article][PubMed]
SahmD. F.,
DeaneJ.,
BienP. A.,
LockeJ. B.,
ZuillD. E.,
ShawK. J.,
BartizalK. F.2015; Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81:112–118 [View Article][PubMed]
ShawK. J.,
PoppeS.,
SchaadtR.,
Brown-DriverV.,
FinnJ.,
PillarC. M.,
ShinabargerD.,
ZurenkoG.2008; In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 52:4442–4447 [View Article][PubMed]
SievertD. M.,
RicksP.,
EdwardsJ. R.,
SchneiderA.,
PatelJ.,
SrinivasanA.,
KallenA.,
LimbagoB.,
FridkinS.National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities2013; Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 34:1–14 [View Article][PubMed]
TsaiH. Y.,
LiaoC. H.,
ChenY. H.,
LuP. L.,
HuangC. H.,
LuC. T.,
ChuangY. C.,
TsaoS. M.,
ChenY. S. et al.2012; Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline in vitro surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother 56:3402–3405 [View Article][PubMed]
WinstonL. G.,
PerlmanJ. L.,
RoseD. A.,
GerberdingJ. L.1999; Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis 29:580–585[PubMed][CrossRef]
WoodfordN.,
LivermoreD. M.2009; Infections caused by gram- positive bacteria: a review of the global challenge. J Infect 59:S4–16 [View Article][PubMed]
In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China